A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2023

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Axitinib

"Avelumab 10 mg/kg will be administered every two weeks. Avelumab is administered as a 1-hour iv infusion, diluted with 0.9% saline solution; Axitinib 5 mg should be taken orally twice daily approximately 12 hours apart with or without food. They should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.~The duration of treatment cycle is 28 days."

Trial Locations (1)

02-781

Maria Sklodowska-Curie National Research Institue of Oncology, Warsaw

All Listed Sponsors
lead

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

NCT04258956 - A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy | Biotech Hunter | Biotech Hunter